Authors
Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo-Yeon Kim, Chang Won Jeong, Dae-Yeon Kim, Hang A Park, Min-Ho Kim, Seong Hwan Kim, Won-Woo Seo, Woo Jin Kim, Young Sung Suh, Rae Woong Park, Ju-Young Shin
Published in
Diabetes, obesity & metabolism. Jul 06, 2026. Epub Jul 06, 2026.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for weight loss, yet their safety in clinical practice remains uncertain. We evaluated associations between weight-management semaglutide or liraglutide initiation and safety outcomes in a multicentre cohort.
We used electronic health records from 13 South Korean hospitals (2018-2025) mapped to the OMOP Common Data Model. Adults initiating semaglutide or liraglutide were compared with propensity score-matched non-initiators in a new-user design. Ten safety outcomes were assessed. Site-specific hazard ratios were estimated using Cox proportional hazards models and combined via meta-analysis.
After matching, 2357 semaglutide and 6953 liraglutide initiators were compared with 22 602 and 68 001 non-initiators, respectively. Semaglutide was associated with increased risks of psychiatric disorders overall (hazard ratio 2.02, 95% confidence interval 1.30-3.14), anxiety disorder (2.39, 1.22-4.71), depressive disorder (3.42, 1.51-7.74), gastrointestinal dysmotility or obstruction (3.91, 1.42-10.82), and vision impairment (1.58, 1.04-2.41). Liraglutide was associated with increased risks of psychiatric disorders overall (1.66, 1.36-2.03), anxiety disorder (1.68, 1.45-1.96), depressive disorder (1.51, 1.14-2.00), hepatic impairment (1.46, 1.16-1.83), pancreatobiliary disorder (1.33, 1.09-1.63), pancreatitis/cholangitis/cholelithiasis (1.40, 1.18-1.68), and vision impairment (1.34, 1.16-1.55). Sensitivity analyses were consistent overall, although semaglutide-associated vision impairment and liraglutide-associated hepatic impairment were not significant in some analyses.
GLP-1 RA initiation for weight loss was associated with higher risks of selected psychiatric and gastrointestinal outcomes compared with non-initiators, with heterogeneity across agents. These findings underscore the importance of careful patient selection and monitoring.
PMID:
42410329
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0